CN1918155B - 作为lxr调节剂的化合物和组合物 - Google Patents
作为lxr调节剂的化合物和组合物 Download PDFInfo
- Publication number
- CN1918155B CN1918155B CN2005800046771A CN200580004677A CN1918155B CN 1918155 B CN1918155 B CN 1918155B CN 2005800046771 A CN2005800046771 A CN 2005800046771A CN 200580004677 A CN200580004677 A CN 200580004677A CN 1918155 B CN1918155 B CN 1918155B
- Authority
- CN
- China
- Prior art keywords
- och
- alkyl
- group
- oxc
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (7)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54384804P | 2004-02-11 | 2004-02-11 | |
US60/543,848 | 2004-02-11 | ||
US62302104P | 2004-10-27 | 2004-10-27 | |
US60/623,021 | 2004-10-27 | ||
PCT/US2005/004655 WO2005077124A2 (en) | 2004-02-11 | 2005-02-11 | Compounds and compositions as lxr modulators |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1918155A CN1918155A (zh) | 2007-02-21 |
CN1918155B true CN1918155B (zh) | 2010-05-26 |
Family
ID=34864533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005800046771A Expired - Fee Related CN1918155B (zh) | 2004-02-11 | 2005-02-11 | 作为lxr调节剂的化合物和组合物 |
Country Status (8)
Country | Link |
---|---|
US (3) | US8158662B2 (zh) |
EP (1) | EP1713799A4 (zh) |
JP (1) | JP5022040B2 (zh) |
CN (1) | CN1918155B (zh) |
AU (2) | AU2005211809B2 (zh) |
BR (1) | BRPI0507632A (zh) |
CA (1) | CA2553443C (zh) |
WO (1) | WO2005077124A2 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101021828B1 (ko) * | 2004-10-27 | 2011-03-17 | 다이이찌 산쿄 가부시키가이샤 | 2 이상의 치환기를 갖는 벤젠 화합물 |
JP4854264B2 (ja) * | 2004-10-27 | 2012-01-18 | 第一三共株式会社 | 2以上の置換基を有するベンゼン化合物 |
ES2620451T3 (es) * | 2009-05-28 | 2017-06-28 | Exelixis Patent Company Llc | Moduladores de los LXR |
CA2811145A1 (en) | 2010-09-07 | 2012-03-15 | Snu R&Db Foundation | Sesterterpene compound and use thereof |
AU2015204572B2 (en) | 2014-01-10 | 2020-07-30 | Inspirna, Inc. | LXR agonists and uses thereof |
EP3402477A4 (en) | 2016-01-11 | 2019-08-21 | The Rockefeller University | METHODS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH SUPPRESSIVE CELLS DERIVED FROM MYELOID CELLS |
WO2019104062A1 (en) | 2017-11-21 | 2019-05-31 | Rgenix, Inc. | Polymorphs and uses thereof |
US11174220B2 (en) | 2019-12-13 | 2021-11-16 | Inspirna, Inc. | Metal salts and uses thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5106859A (en) * | 1988-09-30 | 1992-04-21 | Tsumura & Co. | Certain 1,3,4-thiadiazole derivatives and anti-ulcer agent comprising said derivatives as active ingredient |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01160976A (ja) | 1987-12-18 | 1989-06-23 | Tsumura & Co | 1,3,4−チアジアゾール誘導体及びそれを有効成分として含有する抗潰瘍剤 |
JPH01233282A (ja) | 1988-03-12 | 1989-09-19 | Tsumura & Co | 1,3,4−チアジアゾール誘導体及びそれを有効成分として含有する抗潰瘍剤 |
WO2001032173A1 (fr) | 1999-10-29 | 2001-05-10 | Yamanouchi Pharmaceutical Co., Ltd. | Inhibiteurs de neurocytotoxicite de l'acide kainique |
US6555563B1 (en) * | 2001-11-16 | 2003-04-29 | Medinox, Inc. | Heteroaryl substituted amidinyl and imidazolyl compounds and methods employing same for the treatment of inflammation |
AU2003301216A1 (en) | 2002-12-23 | 2004-07-22 | Irm Llc | Novel use of liver x receptor agonists |
-
2005
- 2005-02-11 AU AU2005211809A patent/AU2005211809B2/en not_active Ceased
- 2005-02-11 WO PCT/US2005/004655 patent/WO2005077124A2/en active Application Filing
- 2005-02-11 BR BRPI0507632-3A patent/BRPI0507632A/pt not_active IP Right Cessation
- 2005-02-11 CA CA2553443A patent/CA2553443C/en not_active Expired - Fee Related
- 2005-02-11 JP JP2006553324A patent/JP5022040B2/ja not_active Expired - Fee Related
- 2005-02-11 EP EP05713521A patent/EP1713799A4/en not_active Withdrawn
- 2005-02-11 CN CN2005800046771A patent/CN1918155B/zh not_active Expired - Fee Related
- 2005-02-11 US US10/589,087 patent/US8158662B2/en not_active Expired - Fee Related
-
2009
- 2009-05-12 AU AU2009201867A patent/AU2009201867C1/en not_active Ceased
-
2012
- 2012-03-07 US US13/414,385 patent/US8569345B2/en not_active Expired - Fee Related
-
2013
- 2013-08-29 US US14/013,482 patent/US20130345220A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5106859A (en) * | 1988-09-30 | 1992-04-21 | Tsumura & Co. | Certain 1,3,4-thiadiazole derivatives and anti-ulcer agent comprising said derivatives as active ingredient |
Also Published As
Publication number | Publication date |
---|---|
AU2009201867A1 (en) | 2009-06-04 |
EP1713799A2 (en) | 2006-10-25 |
US8158662B2 (en) | 2012-04-17 |
US20120214812A1 (en) | 2012-08-23 |
AU2009201867B8 (en) | 2013-05-30 |
WO2005077124A2 (en) | 2005-08-25 |
JP2007522242A (ja) | 2007-08-09 |
AU2005211809B2 (en) | 2009-02-12 |
WO2005077124A3 (en) | 2005-11-10 |
AU2009201867B2 (en) | 2011-12-15 |
US20130345220A1 (en) | 2013-12-26 |
CA2553443C (en) | 2012-03-27 |
AU2009201867C1 (en) | 2013-05-30 |
US20090325981A1 (en) | 2009-12-31 |
EP1713799A4 (en) | 2010-07-07 |
CN1918155A (zh) | 2007-02-21 |
CA2553443A1 (en) | 2005-08-25 |
AU2009201867A8 (en) | 2013-05-30 |
BRPI0507632A (pt) | 2007-07-03 |
JP5022040B2 (ja) | 2012-09-12 |
AU2005211809A1 (en) | 2005-08-25 |
US8569345B2 (en) | 2013-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1918155B (zh) | 作为lxr调节剂的化合物和组合物 | |
TWI643855B (zh) | Fxr (nr1h4) 調節化合物 | |
JP6436463B2 (ja) | 細胞内カルシウムを調節する化合物 | |
CN101466714B (zh) | 作为hm74a激动剂的嘌呤酮衍生物 | |
JP5782377B2 (ja) | 細胞内カルシウムを調節する化合物 | |
JP5112423B2 (ja) | ピリドピリミジノン誘導体 | |
JP4808616B2 (ja) | ピリダジン誘導体および治療剤としてのその用途 | |
JP6503019B2 (ja) | 細胞内カルシウムを調節する化合物 | |
CN102812003B (zh) | 吡咯烷羧酸衍生物、药物组合物以及在代谢紊乱中作为g-蛋白偶联受体43(gpr43)激动剂使用的方法 | |
AU2013283318B2 (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders | |
EP2817292B1 (en) | Sulfonamide compounds and uses as tnap inhibitors | |
EP1398032A1 (en) | 4-Oxo-quinazolines as LXR nuclear receptor binding compounds | |
JP2002332266A (ja) | PPAR−γモジュレータ | |
CN102548974A (zh) | 新型fxr(nr1h4)结合和活性调节化合物 | |
JP2009507791A (ja) | ナイアシン受容体アゴニスト、このような化合物を含有する組成物、および治療方法 | |
CN101309915A (zh) | 作为lxr调节剂的化合物和组合物 | |
JP2000502702A (ja) | 抗ヘルペスウイルス性を有するフェニルチアゾール誘導体 | |
JP2009531365A (ja) | セラミドキナーゼ調節 | |
CN103180316A (zh) | 调节细胞内钙的化合物 | |
JP2010521513A (ja) | アザ−ピリドピリミジノン誘導体 | |
JPWO2003051876A1 (ja) | ピラゾロピリジン誘導体およびその医薬用途 | |
CN102596919A (zh) | 芳香酶抑制剂 | |
JP2019147807A (ja) | 肝臓x受容体(lxr)のモジュレーター | |
CN107912042A (zh) | 用于治疗疾病的稠合双环化合物 | |
WO2002102780A1 (fr) | Compose derive de tetrahydroquinoline et medicament contenant ledit compose comme principe actif |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Molteni Valentina Inventor after: Li Xiaolin Inventor after: Furet Pascal Inventor after: Ellis David Archer Inventor after: Anaclerio Beth Inventor after: Saez Enrique Inventor after: Wityak John Inventor before: Molteni Valentina Inventor before: Li Xiaolin Inventor before: Nabakka Juliet Inventor before: Ellis David Archer Inventor before: Anaclerio Beth Inventor before: Saez Enrique Inventor before: Wityak John |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100526 Termination date: 20150211 |
|
EXPY | Termination of patent right or utility model |